Akari Secures Australian Patent for Core ADC Payload, Bolstering Global IP
Summary
Akari Therapeutics announced it has secured Australian patent approval for its proprietary PH1 RNA splicing modulator ADC payload. This patent covers the core technology used in its antibody-drug conjugate (ADC) pipeline, including the lead candidate AKTX-101. This development significantly strengthens Akari's global intellectual property portfolio, building on recent positive preclinical data and abstract acceptance for AKTX-101. For a micro-cap biotech, robust IP protection is critical as it de-risks the company's assets and enhances its long-term valuation and potential for future partnerships. Investors will continue to monitor the progress of AKTX-101 through IND-enabling studies towards a planned Phase 1 clinical trial in late 2026/early 2027.
At the time of this announcement, AKTX was trading at $5.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.25 to $59.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.